References:
1 Di Muzio NG, Fodor A, Noris Chiorda B, et al. “Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.” Clin Oncol (R Coll Radiol). 2016 Aug;28(8):490-500. doi: 10.1016/j.clon.2016.02.005.
2 Tomita N, Soga N, Ogura Y, et al. “High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes.” J Cancer Res Clin Oncol. 2016 Jul;142(7):1609-19. doi: 10.1007/s00432-016-2173-9.
3 Yamazaki H, Masui K, Suzuki G, et al. “High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer.” Cancers (Basel). 2018 Sep 10;10(9). pii: E322. doi: 1.
4 Macias VA, Barrera-Mellado I. “Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial.” BJU Int. 2019 Oct 15. doi: 10.1111/bju.14925.
5 Fodor A, Berardi G, Fiorino C, et al. “Toxicity and efficacy of salvage carbon 11-choline positron emission tomography/computed tomography-guided radiation therapy in patients with lymph node recurrence of prostate cancer.” BJU Int. 2017 Mar;119(3):406-413.
6 Saldi S, Bellavita R, Lancellotta V, et al. “Acute Toxicity Profiles of Hypofractionated Adjuvant and Salvage Radiation Therapy After Radical Prostatectomy: Results of a Prospective Study.” Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):105-111. doi: 10.10.